BRAF and neoplasm: This is also seen in our cohort in which, in addition to the hyperprogression case, both non-hyperprogression treatment episodes with a 50% increase in volumetric tumor growth per month and a twofold increase in tumor growth experienced previous disease progression on a BRAF inhibitor.